ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Coronavirus

Germany to buy Avigan from Japan to fight coronavirus

Berlin to stockpile millions of doses of Fujifilm's anti-flu drug

Fujifilm-developed Avigan has shown promise as a coronavirus treatment.   © Reuters

FRANKFURT -- The German government will purchase large amounts of the anti-influenza drug Avigan, developed by a unit of Fujifilm Holdings, to treat the new coronavirus, local media reported Thursday.

Berlin is aiming for short-term stockpiling of Avigan, Frankfurter Allgemeine Zeitung reported. The purchase will be in the millions of packs, which will be distributed through university hospitals and other institutions with the help of the military.

A Chinese government-affiliated institution said it has confirmed the efficacy of Avigan, developed by Fujifilm Toyama Chemical, against coronavirus infection in clinical trials, and there are growing expectations that it will help prevent the spread of the pandemic. Fujifilm Toyama Chemical has just begun its own clinical trials.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more